Clinical manifestations of bacteremia caused by Aeromonas species in southern Taiwan

PLoS One. 2014 Mar 10;9(3):e91642. doi: 10.1371/journal.pone.0091642. eCollection 2014.

Abstract

Aim: This study is conducted to investigate the clinical characteristics of patients with bacteremia caused by Aeromonas species.

Materials and methods: Patients with bacteremia caused by Aeromonas species during the period 2009 to 2013 were identified from a computerized database of a regional hospital in southern Taiwan. The medical records of these patients were retrospectively reviewed.

Results: A total of 91 patients with bacteremia due to Aeromonas species were identified. In addition to 16 (17.6%) primary bacteremia, the most common source of secondary infection is peritonitis (n = 27, 29.7%), followed by biliary tract infection (n = 18, 19.8%), and SSTI (n = 12, 13.2%), pneumonia (n = 9, 9.9%), catheter-related bloodstream infection (n = 5, 5.5%), and genitourinary tract infection (n = 4, 4.4%). A. hydrophila (n = 35, 38.5%) was the most common pathogen, followed by A. veronii biovar sobria (n = 31, 34.1%), A. caviae (n = 14, 15.4%), and A. veronii biovar veronii (n = 9, 9.9%). Forty-three (47.3%) patients were classified as healthcare-associated infections (HCAI) causes by Aeromonas species, and patients with HCAI were more likely to have cancer, and receive immunosuppressant than patients with community-acquired bacteremia. The overall outcomes, including rate of ICU admission, acute respiratory failure, and mortality were 33.3%, 28.6%, and 23.1%, respectively. Multivariate analysis showed that the in-hospital day mortality was significantly associated only with underlying cancer (P <.001), and initial shock (P <.001).

Conclusions: Aeromonas species should be considered one of the causative pathogens of healthcare-associated bacteremia, especially in immunocompromised patients. In addition, it can be associated with high fatality. Cancer and initial shock were the poor prognostic factors.

MeSH terms

  • Adolescent
  • Adult
  • Aeromonas / physiology*
  • Aged
  • Aged, 80 and over
  • Anti-Infective Agents / pharmacology
  • Bacteremia / microbiology*
  • Bacteremia / mortality
  • Bacteremia / pathology*
  • Child
  • Community-Acquired Infections / microbiology
  • Community-Acquired Infections / mortality
  • Community-Acquired Infections / pathology
  • Cross Infection / microbiology
  • Cross Infection / mortality
  • Cross Infection / pathology
  • Female
  • Gram-Negative Bacterial Infections / microbiology*
  • Gram-Negative Bacterial Infections / mortality
  • Gram-Negative Bacterial Infections / pathology*
  • Hospital Mortality
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Prognosis
  • Taiwan / epidemiology
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-Infective Agents

Grants and funding

The authors have no support or funding to report.